{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "9356796",
  "DateCompleted": {
    "Year": "1997",
    "Month": "12",
    "Day": "02"
  },
  "DateRevised": {
    "Year": "2019",
    "Month": "12",
    "Day": "10"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [],
    "Journal": {
      "ISSN": "1058-4838",
      "JournalIssue": {
        "Volume": "25",
        "Issue": "4",
        "PubDate": {
          "Year": "1997",
          "Month": "Oct"
        }
      },
      "Title": "Clinical infectious diseases : an official publication of the Infectious Diseases Society of America",
      "ISOAbbreviation": "Clin Infect Dis"
    },
    "ArticleTitle": "Effectiveness of clemastine fumarate for treatment of rhinorrhea and sneezing associated with the common cold.",
    "Pagination": {
      "StartPage": "824",
      "EndPage": "830",
      "MedlinePgn": "824-30"
    },
    "Abstract": {
      "AbstractText": [
        "Limited data support the use of first-generation antihistamines for treatment of the common cold. The purpose of this study was to test the effectiveness of clemastine fumarate, a first-generation antihistamine, for treatment of sneezing and rhinorrhea associated with naturally occurring common colds. Four hundred three subjects (202 clemastine fumarate recipients and 201 placebo recipients) who reported new onset (< 24 hours) of cold symptoms that included rhinorrhea or sneezing were studied. At baseline (day 1), the mean symptom-severity scores +/- SEM for the clemastine fumarate and placebo groups were not significantly different. The mean rhinorrhea-severity score +/- SEM was not different on day 2; however, on day 3, the mean rhinorrhea-severity score +/- SEM was 1.02 +/- 0.07 for the clemastine fumarate group and 1.39 +/- 0.07 for the placebo group (P < .001). This treatment effect persisted on day 4. A significant effect on sneezing was noted on days 2-4. Sedation occurred in 14% of the clemastine fumarate-treated subjects and 1.5% of the placebo-treated subjects (P < .0001)."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Pediatrics, Medical University of South Carolina, Charleston 29425, USA."
          }
        ],
        "LastName": "Turner",
        "ForeName": "R B",
        "Initials": "RB"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Sperber",
        "ForeName": "S J",
        "Initials": "SJ"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Sorrentino",
        "ForeName": "J V",
        "Initials": "JV"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "O'Connor",
        "ForeName": "R R",
        "Initials": "RR"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Rogers",
        "ForeName": "J",
        "Initials": "J"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Batouli",
        "ForeName": "A R",
        "Initials": "AR"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Gwaltney",
        "ForeName": "J M",
        "Initials": "JM",
        "Suffix": "Jr"
      }
    ],
    "PublicationTypeList": [
      "Clinical Trial",
      "Journal Article",
      "Randomized Controlled Trial"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "Clin Infect Dis",
    "NlmUniqueID": "9203213",
    "ISSNLinking": "1058-4838"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Anti-Allergic Agents"
    },
    {
      "RegistryNumber": "95QN29S1ID",
      "NameOfSubstance": "Clemastine"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Adolescent"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Adult"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Aged"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Analysis of Variance"
    },
    {
      "QualifierName": [
        "administration & dosage",
        "therapeutic use"
      ],
      "DescriptorName": "Anti-Allergic Agents"
    },
    {
      "QualifierName": [
        "administration & dosage",
        "therapeutic use"
      ],
      "DescriptorName": "Clemastine"
    },
    {
      "QualifierName": [
        "drug therapy",
        "virology"
      ],
      "DescriptorName": "Common Cold"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Female"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Male"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Middle Aged"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Outcome Assessment, Health Care"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Rhinovirus"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Sneezing"
    }
  ]
}